Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-44,229
Closed -$861K 1040
2025
Q2
$861K Sell
44,229
-37,713
-46% -$557K 0.01% 685
2025
Q1
$1.05M Buy
81,942
+56,699
+225% +$912K 0.03% 472
2024
Q4
$435K Buy
25,243
+5,761
+30% +$115K 0.01% 905
2024
Q3
$440K Buy
+19,482
New +$446K 0.01% 1334
2024
Q2
Sell
-6,220
Closed -$205K 2023
2024
Q1
$205K Sell
6,220
-10,636
-63% -$362K 0.01% 1469
2023
Q4
$613K Buy
+16,856
New +$579K 0.01% 853
2023
Q3
Sell
-12,322
Closed -$472K 1684
2023
Q2
$472K Buy
12,322
+4,622
+60% +$171K 0.01% 857
2023
Q1
$315K Buy
+7,700
New +$322K 0.01% 1035
2021
Q2
Sell
-12,209
Closed -$540K 1358
2021
Q1
$540K Buy
+12,209
New +$461K 0.02% 531

Other funds holding ADNT

Centiva Capital's ADNT Position: Q3 2025 in Review

Centiva Capital sold out of Adient (ADNT) in Q3 2025, closing a stake of 44,229 shares — an estimated $861K sold.

Centiva Capital first reported a position in ADNT in Q1 2021 and held it in 9 quarters. The position peaked at $1.05M in Q1 2025. 288 funds tracked by Wall St. Rank hold ADNT as of Q3 2025.

  • Centiva Capital reported no remaining Adient position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 44,229 Adient shares in Q3 2025, an estimated $861K.
  • Centiva Capital first reported a position in Adient in Q1 2021 and held it in 9 quarters.
  • Centiva Capital's Adient position peaked at $1.05M in Q1 2025.
  • 288 funds tracked by Wall St. Rank held Adient as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.